New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export MRNA’s income statement to Excel — free account
Moderna, Inc.
MRNAModerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.
- Revenue
- +29.2%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- +13,550.0%
Quarter to September 2026, against a year earlier
195.12
4.21
−2.11%
After hours trading: 199.30, up 2.14%, last trade Fri 7:57pm Eastern.
Follow MRNA
Alert me
Revenue to profit Twelve months to Sep 30, 2026
It lost $2.8B on $2.5B of revenue: $110.46 for every $100. Gross margin has risen two quarters running, from 22.1% to 28.0%. What is an income statement?
| Revenue | 2.5 | 100.0% |
|---|---|---|
| Cost of revenue | −1.8 | −72.0% |
| Gross profit | 0.7 | 28.0% |
| Research & development | −2.7 | −105.3% |
| Selling, general & admin | −1.0 | −38.8% |
| Operating income | −2.9 | −116.0% |
| Other income, net | +0.2 | 8.0% |
| Income tax | −0.1 | −2.4% |
| Net income | −2.8 | −110.5% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $1.9B | $2.2B | $2.2B | $2.5B |
| Operating income | −$3.1B | −$3.4B | −$3.3B | −$2.9B |
| Net income | −$2.8B | −$3.2B | −$3.2B | −$2.8B |
| Net margin (right axis) | −145.2% | −143.6% | −141.4% | −110.5% |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Revenue |
+8 more TTM periods Free account |
1,944.00 | 2,225.00 | 2,228.00 | 2,525.00 |
Cost of Revenue |
868.00 | 1,733.00 | 1,707.00 | 1,818.00 | |
Gross Profit |
1,076.00 | 492.00 | 521.00 | 707.00 | |
R&D Expenses |
3,132.00 | 2,925.00 | 2,876.00 | 2,658.00 | |
SG&A Expenses |
1,018.00 | 979.00 | 965.00 | 979.00 | |
Operating Income |
(3,074.00) | (3,412.00) | (3,320.00) | (2,930.00) | |
Non-operating Income/Expense |
306.00 | 274.00 | 233.00 | 201.00 | |
| (2,768.00) | (3,138.00) | (3,087.00) | (2,729.00) | ||
Income Tax Provision |
54.00 | 56.00 | 64.00 | 60.00 | |
Income after Tax |
(2,822.00) | (3,194.00) | (3,151.00) | (2,789.00) | |
Net Income Common |
(2,822.00) | (3,194.00) | (3,151.00) | (2,789.00) | |
EPS (Basic) |
(7.27) | (8.15) | (7.99) | (7.08) | |
EPS (Diluted) |
(7.27) | (8.15) | (7.99) | (7.10) | |
Shares (Basic, Weighted) |
388.25 | 390.50 | 393.00 | 395.75 | |
Shares (Diluted, Weighted) |
388.25 | 390.50 | 393.00 | 403.00 | |
Gross Margin |
55.35% | 22.11% | 23.38% | 28.00% | |
EBIT Margin |
(158.13%) | (153.35%) | (149.01%) | (116.04%) | |
EBT margin |
(142.39%) | (141.03%) | (138.55%) | (108.08%) | |
Net Profit Margin |
(145.16%) | (143.55%) | (141.43%) | (110.46%) | |
Free Cash Flow Margin |
(106.74%) | (72.04%) | (55.83%) | (80.95%) | |
EBITDA |
(2,926.00) | (3,236.00) | (3,130.00) | (2,719.00) | |
EBIT |
(3,074.00) | (3,412.00) | (3,320.00) | (2,930.00) | |
EPS (Diluted, from Cont. Ops) |
(7.25) | (8.14) | (7.98) | (7.09) | |
EPS (Diluted, Consolidated) |
(7.25) | (8.14) | (7.98) | (7.09) | |
EPS (Basic, Consolidated) |
(7.25) | (8.14) | (7.98) | (7.06) | |
Shares (Diluted, Average) |
389.00 | 391.25 | 393.75 | 403.75 | |
EPS (Basic, from Continuous Ops) |
(7.25) | (8.14) | (7.98) | (7.06) | |
Income from Continuous Operations |
(2,822.00) | (3,194.00) | (3,151.00) | (2,789.00) | |
Consolidated Net Income/Loss |
(2,822.00) | (3,194.00) | (3,151.00) | (2,789.00) | |
EBITDA Margin |
(150.51%) | (145.44%) | (140.48%) | (107.68%) | |
Operating Cash Flow Margin |
(96.35%) | (65.89%) | (48.16%) | (70.69%) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 11, 2026